Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 05, 2024 16:30 ET | Source: Mural Oncology, Inc.

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DUBLIN, Ireland, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and protein...
January 08, 2024 07:00 ET | Source: Mural Oncology, Inc.

Mural Oncology Announces Enhancements to Late-Stage Clinical Trials

Strategic changes to ARTISTRY-6 and ARTISTRY-7, both potentially registrational trials of nemvaleukin, are intended to result in more clinically meaningful dataMural intends to nominate development...
November 15, 2023 07:00 ET | Source: Mural Oncology, Inc.

Mural Oncology Launches to Advance Pipeline of Novel Engineered Cytokine Immunotherapies

Mural Oncology Launches to Advance Pipeline of Novel Engineered Cytokine Immunotherapies